Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Six firms are set to join the Nasdaq 100 Index as part of its annual reconstitution, the benchmark’s overseer said Friday.

Leerink analyst Mani Foroohar lowered the firm’s price target on Alnylam to $351 from $370 and keeps a Market Perform rating on the shares.

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

The latest update on Tuesday morning shows Alnylam Pharmaceuticals shares up by 3.84%, trading at $472.0. At this price, ...

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion ...

Alnylam must wait a few months longer for a verdict on its potential blockbuster-in-waiting vutrisiran. The U.S. FDA has slapped a three-month delay on its review of the RNA interference (RNAi) ...

An Alnylam Pharmaceuticals drug that treats nerve pain caused by an inherited protein disorder now has results from a pivotal clinical trial showing the drug also helps patients suffering the ...

In this special bonus episode Talking General Practice speaks to consultant nephrologist Dr Shafi Malik about the heightened ...

The age of RNA interference drugs has arrived. Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company’s lead drug designed ...